XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Condensed Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 28, 2024
Sep. 30, 2023
Operating activities:    
Net loss $ (43,515) $ (187,969)
Less: Loss from discontinued operations, net of tax 0 (74,429)
Net loss from continuing operations (43,515) (113,540)
Adjustments to reconcile net loss to net cash from operating activities:    
Depreciation and amortization 37,150 44,900
Benefit for expected credit losses (613) (695)
Equity-based compensation 8,327 947
Change in fair value of contingent consideration 1,078 429
Deferred income taxes (8,609) (3,540)
Impairment of assets 33,901 78,615
Loss on disposals 0 2,381
Unrealized loss on foreign currency fluctuations (133) 1,397
Other, net 1,559 1,401
Changes in operating assets and liabilities:    
Accounts receivable (4,874) 19,247
Inventories (10,874) (14,123)
Accounts payable and accrued expenses 1,224 (11,067)
Other current and noncurrent assets and liabilities 4,852 787
Net cash from operating activities - continuing operations 19,473 7,139
Net cash from operating activities - discontinued operations 0 (2,169)
Net cash from operating activities 19,473 4,970
Investing activities:    
Proceeds from sale of a business 0 34,897
Purchase of property and equipment (432) (6,993)
Investments and acquisition of distribution rights (709) 0
Net cash from investing activities - continuing operations (1,141) 27,904
Net cash from investing activities - discontinued operations 0 (11,506)
Net cash from investing activities (1,141) 16,398
Financing activities:    
Proceeds from issuance of Class A common stock 1,339 620
Borrowing on revolver 0 64,000
Payment on revolver 0 (49,000)
Debt refinancing costs (1,180) (3,661)
Payments on long-term debt (11,320) (38,264)
Other, net (564) (334)
Net cash from financing activities (11,725) (26,639)
Effect of exchange rate changes on cash (497) 261
Net change in cash, cash equivalents and restricted cash 6,110 (5,010)
Cash, cash equivalents and restricted cash at the beginning of the period 36,964 31,837
Cash, cash equivalents and restricted cash at the end of the period 43,074 26,827
Supplemental disclosure of noncash investing and financing activities    
Accrued liabilities for intellectual property 0 709
Accounts payable for purchase of property, plant and equipment $ 113 $ 1,304